Original Contribution
Prevalence and Severity of Urogenital Symptoms in Postmenopausal Women Receiving Endocrine Therapy for Breast Cancer

https://doi.org/10.3816/CBC.2009.n.020Get rights and content

Abstract

Background

Data from randomized trials in postmenopausal women receiving endocrine therapy for breast cancer would suggest that the incidence of significant urogenital symptoms is around 40%. As there are inherent reporting biases associated with clinical trials, we sought to assess the prevalence, severity, and effect of urogenital side effects of endocrine therapy in the non-trial setting.

Patients and Methods

A cross-sectional survey study was undertaken and questionnaires used to assess vulvovaginal and urinary tract symptoms in a group of postmenopausal women receiving endocrine therapy for breast cancer.

Results

A total of 251 women were surveyed. Sixty-three percent (158) reported urogenital symptoms. Vaginal dryness was the most common vaginal symptom, occurring in 121 women (48%). This was rated as severe or very severe in 56 of 121 (46%). Thirty-one of 251 (12%) women experienced urinary symptoms. A total of 68 women (27%) had used some form of treatment for vaginal symptoms. Nine women (4%) had considered discontinuing treatment because of urogenital side effects.

Conclusion

Urogenital side effects are common and often severe in women receiving endocrine therapy for breast cancer. The prevalence in this study was 63%, which is higher than that reported in the clinical trial literature. Less than one third of patients had used some form of treatment for these symptoms. This highlights the need for increased recognition and management of the urogenital side effects of estrogen deprivation therapy and raises the concern of the risk of non-compliance with potentially curative adjuvant therapy.

References (32)

  • B Thurlimann et al.

    A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    N Engl J Med

    (2005)
  • RC Coombs et al.

    A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

    N Engl J Med

    (2004)
  • H Mourisden et al.

    Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

    J Clin Oncol

    (2001)
  • JM Naboholtz et al.

    Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimedex Study Group

    J Clin Oncol

    (2000)
  • IE Smith et al.

    Aromatase Inhibitors in Breast Cancer

    N Engl J Med

    (2003)
  • A Goldhirsch et al.

    Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

    J Clin Oncol

    (2001)
  • Cited by (63)

    • The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis

      2019, Clinical Breast Cancer
      Citation Excerpt :

      The first line of non-hormone therapy includes widely available paraben-free vaginal moisturizers and lubricants (water, mineral or plant oil, or silicone-based), especially in women with mild to moderate symptoms of genitourinary syndrome of menopause.13 Vaginal estrogen therapy can restore normal, complex physiological functions of estrogens in the female lower urogenital tract14-17 and is reserved for the treatment of the patients with severe symptoms of VVA.18 However, this therapeutic modality use in patients with estrogen receptor-positive (ER+) breast cancer continues to be debated because of concerns regarding long-term safety.

    • The Impact of Vaginal Laser Treatment for Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Systematic Review and Meta-analysis

      2019, Clinical Breast Cancer
      Citation Excerpt :

      GSM affects 20% to 50% of women after menopause.4-6 In patients with BC, who undergo menopause at an accelerated rate (eg, drug-induced such as with chemotherapy, or use of chemical ovarian suppression with GnRH agonists) or undergo a more severe degree of hypo-estrogenic state owing to use of aromatase inhibitor therapy, symptoms of GSM can occur sooner and be more severe than those found among women with a normal-paced menopause.7-9 Symptoms are often not disclosed by patients because of embarrassment.

    View all citing articles on Scopus

    This article might include the discussion of investigational and/or unlabeled uses of drugs and/or devices that might not be approved by the FDA.

    Electronic forwarding or copying is a violation of US and international copyright laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.

    View full text